The efficacy advantage of evolocumab (AMG 145) dosed at 140 mg every 2 weeks versus 420 mg every 4 weeks in patients with hypercholesterolemia: Evidence from …
XX He, R Zhang, PY Zuo, YW Liu, XN Zha… - European Journal of …, 2017 - Elsevier
Abstract Background Evolocumab (AMG 145), a PCSK9 inhibitor, has been shown to
decrease low-density lipoprotein cholesterol (LDL-C) levels. Doses of 140 mg administered …
decrease low-density lipoprotein cholesterol (LDL-C) levels. Doses of 140 mg administered …
[HTML][HTML] Review of Evolocumab for the Reduction of LDL Cholesterol and Secondary Prevention of Atherosclerotic Cardiovascular Disease
Elevated low-density lipoprotein cholesterol (LDL-C) is a major causal factor for
atherosclerotic cardiovascular disease (ASCVD), the leading cause of mortality worldwide …
atherosclerotic cardiovascular disease (ASCVD), the leading cause of mortality worldwide …
Low-density lipoprotein cholesterol levels exceed the recommended European threshold for PCSK9i initiation: lessons from the HEYMANS study
KK Ray, N Dhalwani, M Sibartie… - … Journal-Quality of …, 2022 - academic.oup.com
Aims To describe the characteristics of patients receiving evolocumab in clinical practice
across 12 European countries and simulate the association between low-density lipoprotein …
across 12 European countries and simulate the association between low-density lipoprotein …
Evolocumab lowers LDL cholesterol
K Huynh - Nature Reviews Cardiology, 2014 - nature.com
Familial hypercholesterolaemia is characterized by impaired lipoprotein metabolism and
elevated plasma concentrations of LDL cholesterol, which is associated with an increased …
elevated plasma concentrations of LDL cholesterol, which is associated with an increased …
A comparison of ezetimibe and evolocumab for atherogenic lipid reduction in four patient populations: a pooled efficacy and safety analysis of three phase 3 studies
MJ Koren, PH Jones, JG Robinson, D Sullivan… - Cardiology and …, 2020 - Springer
Introduction Clinicians, payers, guideline committees, and policymakers support the use of
high-intensity statins in patients at high risk for complications of cardiovascular disease …
high-intensity statins in patients at high risk for complications of cardiovascular disease …
Design and rationale of the GAUSS‐2 study trial: a double‐blind, ezetimibe‐controlled phase 3 study of the efficacy and tolerability of evolocumab (AMG 145) in …
L Cho, M Rocco, D Colquhoun, D Sullivan… - Clinical …, 2014 - Wiley Online Library
Statins effectively lower low‐density lipoprotein cholesterol (LDL‐C), reducing
cardiovascular morbidity and mortality. Most patients tolerate statins well, but approximately …
cardiovascular morbidity and mortality. Most patients tolerate statins well, but approximately …
One-year efficacy and safety of evolocumab in Japanese patients―A pooled analysis from the open-label extension OSLER studies―
A Hirayama, S Yamashita, H Inomata… - Circulation …, 2017 - jstage.jst.go.jp
Background: Evolocumab, a fully human monoclonal antibody against PCSK9, significantly
reduced low-density lipoprotein-cholesterol (LDL-C) levels in Japanese patients by up to …
reduced low-density lipoprotein-cholesterol (LDL-C) levels in Japanese patients by up to …
The efficacy of evolocumab in the management of hyperlipidemia: a systematic review
L AlHajri, A AlHadhrami, S AlMheiri… - Therapeutic …, 2017 - journals.sagepub.com
Background: Hyperlipidemia or dyslipidemia has been a concern for a long time, with
various guidelines emphasizing the importance of managing the lipid profile to prevent …
various guidelines emphasizing the importance of managing the lipid profile to prevent …
[HTML][HTML] Long-term persistence with evolocumab treatment and sustained reductions in LDL-cholesterol levels over 30 months: final results from the European …
KK Ray, E Bruckert, P Peronne-Filardi, C Ebenbichler… - Atherosclerosis, 2023 - Elsevier
Background and aims Variability in low-density lipoprotein-cholesterol (LDL-C) level control
at a population level is associated with poor cardiovascular outcomes. Limited data exist on …
at a population level is associated with poor cardiovascular outcomes. Limited data exist on …
Interindividual variation in low-density lipoprotein cholesterol level reduction with evolocumab: an analysis of FOURIER trial data
A Qamar, RP Giugliano, AC Keech, JF Kuder… - JAMA …, 2019 - jamanetwork.com
Importance Little is known about the heterogeneity in low-density lipoprotein cholesterol
levels (LDL-C) lowering with proprotein convertase subtilisin kexin 9 (PCSK9) inhibitor …
levels (LDL-C) lowering with proprotein convertase subtilisin kexin 9 (PCSK9) inhibitor …